Shingrix Side Effects. Last month, the Food and Drug Administration approved Shingrix (by GlaxoSmithKline) for the prevention of shingles among adults aged 50 and over. This approval came after a clinical trial involving 38,000 people which demonstrated the efficacy of the vaccine. In this trial, participants who were given Shingrix demonstrated efficacy against shingles greater than 90%. Moreover, follow-ups over a period of four years has shown the sustained efficacy of the vaccine.
Shingrix was developed specifically to overcome the age-related decline in immunity to shingles (herpes zoster) which, currently, affects 1 in 3 people in the United States. Want more vaccine side effects?